ImCheck HP

Exploring uncharted territories in immunomodulation
Butyrophilins & Gamma-delta T cells

ImCheck Therapeutics is driving innovation in immune system modulation based on our unique know-how in the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules. We are designing the next generation of immunotherapeutic antibodies for the treatment of cancer, infectious disease, and autoimmune disease.

Latest news


ImCheck Receives FDA Fast Track Designation for ICT01 in Combination with Azacitidine and Venetoclax in First-Line Acute Myeloid Leukemia for Patients Unfit for Induction Chemotherapy Treatment
Science & Medicine 
Read more
ImCheck Awarded EUR 20.18 Million from the French Government Through the France 2030 Investment and Innovation Plan
Financial & Business  Leadership & Corporate 
Read more
ImCheck Appoints Stephan Braun as Chief Medical Officer
Leadership & Corporate 
Read more

Festival of Biologics Europe

From  Oct 15, 2024  to  Oct 17, 2024 

Read more

PEGS Europe

From  Nov 05, 2024  to  Nov 07, 2024 

Read more

ASH ANNUAL MEETING

From  Dec 07, 2024  to  Dec 10, 2024 

Read more

STAY IN TOUCH WITH OUR LATEST NEWS

Subscribe to receive our press releases and related news